Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00571675 · ClinicalTrials.gov registry record · Phase 2
A Study Comparing AT-101 in Combination With Docetaxel and Prednisone Versus Docetaxel and Prednisone in Men With Chemotherapy-Naïve Metastatic Hormone Refractory Prostate Cancer (HRPC)
A Phase 2 study, sponsored by Ascenta Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 220
- Enrollment target
NCT00571675: Completed Phase 2 study, sponsored by Ascenta Therapeutics.
NCT00571675 is a Phase 2 study that has completed, run by Ascenta Therapeutics. The registered enrollment target is 220 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (65% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00571675, a Phase 2 study, has completed, sponsored by Ascenta Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 220 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, placebo-controlled, multinational Phase 2 study to evaluate and compare oral AT-101 in combination with docetaxel and prednisone versus docetaxel and prednisone plus placebo in the treatment of chemotherapy-naïve metastatic hormone-refractory prostate cancer, who have received hormonal therapy but not chemotherapy.
Interventions
- DRUG AT-101, prednisone and docetaxel
- DRUG placebo, prednisone and docetaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2007-10 |
| Est. Completion | 2010-09 |
| Phase | Phase 2 |
What the finished NCT00571675 record still lists
NCT00571675 is an interventional study that assigns participants to a tested intervention. The registered 220 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (65% higher).
The record links to 0 conditions, and to 2 interventions - of which AT-101, prednisone and docetaxel is the first listed.
NCT00571675 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00571675 about?
NCT00571675 is a clinical study titled "A Study Comparing AT-101 in Combination With Docetaxel and Prednisone Versus Docetaxel and Prednisone in Men With Chemotherapy-Naïve Metastatic Hormone Refractory Prostate Cancer (HRPC)". This is a randomized, double-blind, placebo-controlled, multinational Phase 2 study to evaluate and compare oral AT-101 in combination with docetaxel and prednisone versus docetaxel and prednisone plus placebo in the treatment of chemotherapy-naïve metastatic hormone-refractory prostate cancer, who ...
What is the current status of trial NCT00571675?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 220 participants. The study started on 2007-10. Estimated completion is 2010-09.
What interventions are being tested in trial NCT00571675?
The interventions under investigation include: AT-101, prednisone and docetaxel (DRUG), placebo, prednisone and docetaxel (DRUG).
Who is sponsoring clinical trial NCT00571675?
This trial is sponsored by Ascenta Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00571675's enrollment target sits among peer trials
220 275th of 2000 higher than 1,718 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00920972 · 220 participants · Phase 1
Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases
- NCT01851642 · 220 participants
Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs
- NCT02582021 · 220 participants
WISE CVD - Continuation (WISE HFpEF)
- NCT04067830 · 220 participants · Phase 2
Respiratory Muscle Training Before Surgery in Preventing Lung Complications in Patients With Stage I-IIIB Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia